Cytovation is focused on developing innovative immunotherapy solutions to enhance the immune system's ability to recognize and eliminate tumors, particularly those associated with the Wnt/β-catenin signaling pathway. Their lead product, CY-101, employs novel peptide engineering to expose tumor neoantigens, which are unique markers on cancer cells, thereby enabling the immune system to mount a targeted response. Additionally, CY-101 inhibits mechanisms that contribute to tumor growth and immune evasion, making it a promising candidate for treating various solid tumors.

The technology behind CY-101 is characterized by its dual mode of action: it selectively disrupts cancer cell membranes to release neoantigens and simultaneously inhibits the β-catenin pathway, which is crucial for tumor proliferation. This approach not only stimulates a systemic immune response but also directly targets the pathways that allow tumors to thrive. Cytovation's commitment to advancing this technology is reflected in their ongoing clinical trials, which aim to evaluate the efficacy of CY-101 in various cancer types, including adrenocortical carcinoma and colorectal cancer, both as a monotherapy and in combination with other treatments.

Norway

Cytovation is a clinical-stage immuno-oncology biotech focused on the development of CyPep-1, a first-in-class tumor membrane immunotherapy for the treatment of various diseases, including benign tumors and malignant cancers.

Cytovation

Company Details